About Sysmex

With our business centered on the field of in vitro diagnostics, Sysmex provides instruments,

ABOUT SYSMEX reagents, and software to medical institutions and other customers worldwide.

We have created a structure for consistent research and development, production, sales, service and support in response to the diversified needs of our customers with various issues. In addition to producing high-quality instruments, reagents, and software for in vitro diagnostics, this structure allows us to offer high value-added products and services with regard to system products, online support, and advanced scientific information, which have been highly evaluated by our customers worldwide.

Sysmex's Main Business Domains (In Vitro Diagnostics)

Prevention

In Vitro Diagnostics

Hematology*

Examination

Testing that measures and analyzes the number, type, and size of red,

white and other blood cells

(Anemia, leukemia, thrombocytopenia, etc.)

Hemostasis

TestingLaboratoryClinical

Testing that measures the ability of blood to clot at wound sites and dissolve clots

andTreatmentDiagnosis,

(Hemophilia, myocardial infarction, cerebra linfarction, etc.)

Clinical chemistry*

Urinalysis*

Testing to determine the presence of sugar, proteins or blood in the urine

(Kidney stones, kidney disease, diabetes, etc.)

Immunochemistry

Testing for the quantities and status of viruses, hormones and proteins

(Infectious diseases (hepatitis B and C), thyroid disease, various cancers,

Monitoring

myocardial infarction, hepatitis, atopic dermatitis, etc.)

Testing to determine the state of metabolism-related organs by studying sugars,

lipids, proteins and others

(Diabetes, arteriosclerosis, liver dysfunction, kidney dysfunction, etc.)

Gene testing

Through the detection and analysis of cancer genes, this testing contributes to

Recovery

decisions on treatment protocols and drug administration.

(Breast cancer, lung cancer, colorectal cancer, etc.)

* Diagnostics used for medical checkups as well

Company Profile

Name : SYSMEX CORPORATION

Established : February 20, 1968

Paid-in Capital : ¥14,112.0 million (As of March 31, 2022)

Listings : Tokyo Stock Exchange, Prime Market (Ticker Code: 6869)

Directors : Chairman and CEO Hisashi Ietsugu

Head Office : 1-5-1Wakinohama-kaigandori,Chuo-ku, Kobe, Hyogo 651-0073, Japan

■Lines of Businesses : Development, manufacture, sales and export/import of diagnostic instruments, reagents and related software

■Main Customers : National and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc.

Export Destinations : More than 190 countries and regions

Financial Performance

Net Sales

Net Sales by Destination

Sales by Business

363.7billion

363.7 (¥ billion)

Others 4.6%

Medical robotics

Net sales

(Up 19.2% year on year)

Asia Pacific

Japan

Life science

business 0.4%

Euro

130.6 (¥)

8.1%

15.3%

4.9%

Hematology

Clinical

112.4 (¥)

57.8%

chemistry

US dollar

China

0.8%

25.7%

FY2021

Immuno-

FY2021

Yuan

17.5 (¥)

chemistry

2012 2013 2014 2015 2016 2017

2018 2019 2020

2021 (FY)

EMEA*

Americas

5.6%

Japanese GAAP

IFRS

Hemostasis

Reagent sales grew substantially, thanks to a recovery

27.9%

23.0%

17.1%

FCM 0.6%

in testing demand. Net sales also rose significantly,

owing to an expansion of our direct sales area, an

* EMEA: Europe, the Middle East, and Africa

Urinalysis 8.2%

increase in the installed instrument base and a boost

in demand for testing related to COVID-19.

Non-Financial Performance

Japan

Americas

3,888

12

1,341

10

9,812

77

Employees

Companies

(Group total)

(Group total)

China

779

4

Asia Pacific

EMEA

984

12

2,820

39

Sysmex Sustainability Data Book 2022 2

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Sysmex Corporation published this content on 24 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 October 2022 08:03:05 UTC.